🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

57 results for “GSK” Clear

  1. GSK2330672

    ELITE PHARMACEUTICALS INC /NV/

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  2. GSK233705 12.5mcg

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 2 small molecule completed

    1 trial

  3. GSK256066

    GlaxoSmithKline

    Asthma

    phase 2 small molecule completed

    1 trial

  4. GSK3196165 Dose 1

    GlaxoSmithKline

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  5. GSK4418959

    IDEAYA Biosciences

    Neoplasms, Colorectal

    phase 2 small molecule active

    1 trial

  6. GSK4527226

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  7. GSK598809

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  8. GSK962040 50 mg

    GlaxoSmithKline

    Gastroparesis

    phase 2 small molecule terminated

    2 trials

  9. Isis 420915/GSK 299872

    IONIS PHARMACEUTICALS INC

    Amyloidosis

    phase 2 small molecule terminated

    1 trial

  10. Placebo for GSK3739937 Tablets are tablets for oral administration and visually match the active GSK3739937 Tablets with the omission of the active ingredient. Placebo for GSK3739937 Tablets are white, round, film coated tablets containing no markings.

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  11. Placebo for GSK5784283.

    GlaxoSmithKline

    Asthma

    phase 2 small molecule active

    1 trial

  12. Placebo to Match GSK3915393 Tablet

    GlaxoSmithKline

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  13. Placebo to Match GSK3965193 Tablets

    GlaxoSmithKline

    Hepatitis B

    phase 2 small molecule active

    1 trial

  14. Tablets are oval, biconvex, plain and white to off white, Placebo for GSK4011499 Tablets are tablets for oral administration. Tablets are oval, biconvex, plain, and white to off white.

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 2 small molecule active

    1 trial

  15. Trametinib (GSK1120212)

    ADIAL PHARMACEUTICALS, INC.

    Melanoma

    phase 2 small molecule completed

    1 trial

  16. A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination with Anticancer Agents in Participants with Selected Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  17. A Phase 1 study of GSK5764227 in participants with advanced solid tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  18. A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial

  19. A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese and Japanese Participants, and Participants with Interstitial Lung Disease Associated with Connective Tissue Disease (CTD-ILD)

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  20. A phase 1 study of GSK2857916 + Standard of Care (SOC) in first line multiple myeloma patients (DREAMM-9)

    GlaxoSmithKline

    Multiple Myeloma

    phase 1 other active

    1 trial

  21. A study for GSK3862995B in healthy participants and participants with Chronic Obstructive Pulmonary Disease

    GlaxoSmithKline

    Pulmonary Disease, Chronic Obstructive

    phase 1 other active

    1 trial

  22. A study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK4771261 in healthy participants and participants with autosomal dominant polycystic kidney disease.

    GlaxoSmithKline

    Kidney Disease

    phase 1 other active

    1 trial

  23. A study to investigate the pharmacokinetics of a combined oral contraceptive when given alone and in combination with GSK3036656 in female participants of non-childbearing potential aged 18 to 65 years of age

    GlaxoSmithKline

    Tuberculosis

    phase 1 other active

    1 trial

  24. A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants aged 18 to 75 with moderate to severe systemic lupus erythematosus

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources